For example, the afatnib/trametinib combination elicited a complete response for a representative heterogeneous MET-negative tumor cell population comprised of (89% EGFRL858R, 10% EGFRL858R BRAFV600E, 1% EGFRL858R, T790M) compared to rapid progression for its MET activated analog (Fig. 3C). Here, MET is linked to neoplasm.